382 related articles for article (PubMed ID: 27146870)
1. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
Oppel-Heuchel H; Grimm MO
Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
[TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
3. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
5. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
12. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
13. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
14. [Renaissance of immuno-oncology for urological tumors : Current status].
Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
[TBL] [Abstract][Full Text] [Related]
15. [Adverse events of immune checkpoint inhibitors].
Foller S; Oppel-Heuchel H; Fetter I; Winkler Y; Grimm MO
Urologe A; 2017 Apr; 56(4):486-491. PubMed ID: 28246759
[TBL] [Abstract][Full Text] [Related]
16. Immune modulation in cancer with antibodies.
Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
[TBL] [Abstract][Full Text] [Related]
17. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
19. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]